Characteristics and Use Patterns of Patients Taking First-Generation Depot Antipsychotics or Oral Antipsychotics for Schizophrenia
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Investigators compared patient characteristics and antipsychotic use patterns between individuals with schizophrenia treated in usual care with first-generation depot antipsychotics and those treated with oral antipsychotics (first- or second-generation or both). METHODS: Analyses used data from the U.S. Schizophrenia Care and Assessment Program, a large, prospective study of treatment for schizophrenia conducted July 1997 through September 2003. Participants were assessed at enrollment and every six months thereafter with patient self-report, validated psychiatric measures, and systematic extraction of medical records. Individuals treated with a first-generation depot antipsychotic at any time during the three-year study (N=569) were compared with those treated with only oral antipsychotics (N=1,617) on characteristics at enrollment and medication use pattern during the year after enrollment. RESULTS: Compared with patients receiving only oral antipsychotics, participants treated with depot medications (haloperidol or fluphenazine decanoate) were more likely to be African American (p<.001); less likely to be a veteran (p=.005); had more psychiatric hospitalizations in the year before enrollment (p<.001); and were more likely to have been arrested (p<.001), to use alcohol and illicit substances (p<.001), and to show higher psychopathology, particularly psychotic symptoms and disorganized thinking (p<.01 for both). In the year after enrollment, participants treated with depot medications had a high mean medication possession ratio (91%), and most of the medication regimens (68%) were augmented with oral antipsychotics for prolonged durations (median of 144 days). CONCLUSIONS: Patients with schizophrenia treated with first-generation depot antipsychotics differed from those treated with only oral antipsychotics. Findings suggest that first-generation depot antipsychotics might address some unmet needs of a unique subgroup of patients with schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Global Assessment Scale: A Procedure for Measuring Overall Severity of Psychiatric Disturbance
Endicott, J. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770060086012 · Cited by 4,982
Compliance With Medication Regimens for Mental and Physical Disorders
Cramer, J. A., & Rosenheck, R. (1998) · Psychiatric Services · doi:10.1176/ps.49.2.196 · Cited by 725
Gilmer, T. P., Dolder, C. R., Lacro, J. P., Folsom, D. P., Lindamer, L., Garcia, P., & Jeste, D. V. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.4.692 · Cited by 603
Svarstad, B. L., Shireman, T. I., & Sweeney, J. K. (2001) · Psychiatric Services · doi:10.1176/appi.ps.52.6.805 · Cited by 281
Cited by
Tiihonen, J., Haukka, J., Taylor, M., Haddad, P. M., Patel, M. X., & Korhonen, P. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10081224 · Cited by 619
Olfson, M., Blanco, C., Liu, S.-M., Wang, S., & Correll, C. U. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2012.647 · Cited by 352
Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia
Taipale, H., Mittendorfer-Rutz, E., Alexanderson, K., Majak, M., Mehtälä, J., Hoti, F., Jedenius, E., Enkusson, D., Leval, A., Sermon, J., et al. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2017.12.010 · Cited by 262
“Among the commonly used antipsychotics, levomepromazine was associated with the highest mortality, which is in linewith previous geriatric and schizophrenia cohort studies (Kiviniemi et al., 2013; Sahlberg et al., 2015; Schmedt et al., 2016; Shi et al., 2007).”
Kaplan, G., Casoy, J., & Zummo, J. (2013) · Patient Preference and Adherence · doi:10.2147/ppa.s53795 · Cited by 201
Clinical benefits and impact of early use of long‐acting injectable antipsychotics for schizophrenia
Stevens, G. L., Dawson, G., & Zummo, J. (2016) · Early Intervention in Psychiatry · doi:10.1111/eip.12278 · Cited by 109
“Further, LAIs provide the added benefit versus oral APs of addressing problems with daily adherence.(20,21) Although LAIs traditionally have been reserved for patients at later periods of their disease, increasingly, LAI use is being advocated for early episodes of schizophrenia including after first hospitalization t…”
BackgroundIyer, S., Banks, N., Roy, M.-A., Tibbo, P., Williams, R., Manchanda, R., Chue, P., & Malla, A. (2013) · The Canadian Journal of Psychiatry · doi:10.1177/088740341305805s04 · Cited by 81
Offord, S., Wong, B., Mirski, D., Baker, R. A., & Lin, J. (2013) · Journal of Medical Economics · doi:10.3111/13696998.2012.751025 · Cited by 62
Effectiveness of long-acting injectable antipsychotics: a clinical perspective
Castillo, E. G., & Stroup, T. S. (2015) · Evidence Based Mental Health · doi:10.1136/eb-2015-102086 · Cited by 28
Metadata
- Authors
- Shi, L., Ascher-Svanum, H., Zhu, B., Faries, D., Montgomery, W., & Marder, S. R.
- Venue
- Psychiatric Services
- Published
- 2007-04-01
- Volume
- 58
- Issue
- 4
- Pages
- 482-488
- ISSN
- 0022-1597 (ISSN-L)
- 1075-2730
- OpenAlex
- W2065705954
- Cited by
- 112
- References
- 4
- FWCI
- 3.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.